The University of Chicago, Chicago, Illinois.
JAMA Netw Open. 2021 Mar 1;4(3):e214117. doi: 10.1001/jamanetworkopen.2021.4117.
Deficient (ie, <20 ng/mL) or insufficient (ie, 20 to <30 ng/mL) 25-hydroxyvitamin D (also known as calcifediol) levels are more common in Black individuals than White individuals and are associated with increased coronavirus disease 2019 (COVID-19) risk. Whether COVID-19 risk is associated with differences in vitamin D levels of 30 ng/mL or greater is not known.
To examine whether COVID-19 test results are associated with differences in vitamin D levels of 30 ng/mL or greater, including for White individuals and for Black individuals.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study was conducted at an academic medical center in Chicago, Illinois. Participants included individuals with data on vitamin D level within 365 days before COVID-19 testing, which was conducted from March 3 to December 30, 2020. Data were analyzed from September 11, 2020, to February 5, 2021.
The last vitamin D level before COVID-19 testing was categorized as less than 20 ng/mL (ie, deficient), 20 to less than 30 ng/mL (ie, insufficient), 30 to less than 40 ng/mL, or 40 ng/mL or greater. Treatment was defined by vitamin D type and dose 14 days before COVID-19 testing and treatment changes after last vitamin D level.
The main outcome was a positive result for COVID-19 in polymerase chain reaction testing. Multivariable analyses tested whether previously measured vitamin D level was associated with having test results positive for COVID-19 in White individuals and in Black individuals, controlling for months and treatment changes since the vitamin D level was measured, as well as demographic characteristics and comorbidity indicators.
A total of 4638 individuals (mean [SD] age 52.8 [19.5] years; 3205 [69%] women) had data for a vitamin D level within 1 year before COVID-19 testing, including 2288 (49%) Black individuals, 1999 (43%) White individuals, and 351 individuals (8%) who were another race/ethnicity (eg, Asian, Mideast Indian, >1 race). Stratified by vitamin D level, 1251 individuals (27%) had less than 20 ng/mL, 1267 individuals (27%) had 20 to less than 30 ng/mL, 1023 individuals (22%) had 30 to less than 40 ng/mL, and 1097 individuals (24%) had 40 ng/mL or greater. Lower vitamin D levels were more common in Black individuals (<20 ng/mL: 829 of 2288 Black individuals [36%]) than White individuals (<20 ng/mL: 315 of 1999 White individuals [16%]). A total of 333 individuals (7%) had test results positive for COVID-19, including 102 White individuals (5%) and 211 Black individuals (9%). Multivariate analysis controlling for time since last vitamin D level measurement was used to estimate the outcomes associated with levels 14 days before COVID-19 testing. A positive test result for COVID-19 was not significantly associated with vitamin D levels in White individuals but was associated with vitamin D levels in Black individuals (compared with ≥40 ng/mL: <20 ng/mL incidence rate ratio [IRR], 2.55 [95% CI, 1.26-5.15]; P = .009; 20 to <30 ng/mL IRR, 1.69 [95% CI, 0.75-3.84]; P = .21; 30 to <40 ng/mL IRR, 2.64 [95% CI, 1.24-5.66]; P = .01). Stratified by vitamin D level, estimated COVID-19 positivity rates in Black individuals were 9.72% (95% CI, 6.74%-13.41%) for individuals with a vitamin D level less than 20 ng/mL, 6.47% (95% CI, 3.33%-10.28%) for individuals with a vitamin D level of 20 to less than 30 ng/mL, 10.10% (95% CI, 6.00%-15.47%) for individuals with a vitamin D level of 30 to less than 40 ng/mL, and 3.82% (95% CI, 1.78%-6.68%) for individuals with a vitamin D level of 40 ng/mL or higher. Multivariate analysis in individuals with a vitamin D level of 30 ng/mL or greater found that the IRR of a positive COVID-19 test result was 0.97 (95% CI, 0.94-0.99; P = .008) per 1-ng/mL increase in vitamin D overall and 0.95 (95% CI, 0.91-0.98; P = .003) per 1-ng/mL increase in vitamin D in Black individuals.
In this single-center retrospective cohort study, COVID-19 risk increased among Black individuals with vitamin D level less than 40 ng/mL compared with those with 40 ng/mL or greater and decreased with increasing levels among individuals with levels greater than 30 ng/mL. No significant associations were noted for White individuals. Randomized clinical trials should examine whether increasing vitamin D level to greater than 40 ng/mL affects COVID-19 risk.
与白人个体相比,黑人个体中缺乏(<20ng/mL)或不足(20 至<30ng/mL)25-羟维生素 D(也称为钙二醇)的情况更为常见,并且与 2019 年冠状病毒病(COVID-19)风险增加有关。维生素 D 水平为 30ng/mL 或更高是否与 COVID-19 风险相关尚不清楚。
研究 COVID-19 检测结果是否与维生素 D 水平为 30ng/mL 或更高相关,包括白人个体和黑人个体。
设计、地点和参与者:这是一项在伊利诺伊州芝加哥市的一家学术医疗中心进行的回顾性队列研究。参与者包括在 COVID-19 检测前 365 天内有维生素 D 水平数据的个体,COVID-19 检测于 2020 年 3 月 3 日至 12 月 30 日进行。数据分析于 2020 年 9 月 11 日至 2021 年 2 月 5 日进行。
COVID-19 检测前的最后一次维生素 D 水平分为<20ng/mL(即缺乏)、20 至<30ng/mL(即不足)、30 至<40ng/mL 或 40ng/mL 或更高。治疗定义为 COVID-19 检测前 14 天的维生素 D 类型和剂量以及上次维生素 D 水平后治疗的变化。
主要结果是聚合酶链反应检测呈 COVID-19 阳性。多变量分析测试了以前测量的维生素 D 水平是否与白人个体和黑人个体的 COVID-19 检测结果呈阳性相关,控制了自测量维生素 D 水平以来的月份和治疗变化,以及人口统计学特征和合并症指标。
共有 4638 名个体(平均[标准差]年龄 52.8[19.5]岁;3205[69%]名女性)在 COVID-19 检测前 1 年内有维生素 D 水平数据,包括 2288 名(49%)黑人个体、1999 名(43%)白人个体和 351 名(8%)其他种族/族裔(例如,亚洲人、中东印第安人、>1 个种族)。按维生素 D 水平分层,1251 名个体(27%)<20ng/mL,1267 名个体(27%)20 至<30ng/mL,1023 名个体(22%)30 至<40ng/mL,1097 名个体(24%)40ng/mL 或更高。黑人个体中较低的维生素 D 水平更为常见(<20ng/mL:2288 名黑人个体中 829 名[36%])而非白人个体(<20ng/mL:1999 名白人个体中 315 名[16%])。共有 333 名个体(7%)COVID-19 检测结果呈阳性,包括 102 名白人个体(5%)和 211 名黑人个体(9%)。使用 COVID-19 检测前 14 天的维生素 D 水平来估计与水平相关的结果的多变量分析控制了时间因素。白人个体中 COVID-19 检测结果呈阳性与维生素 D 水平无显著关联,但与黑人个体中 COVID-19 检测结果呈阳性与维生素 D 水平相关(与≥40ng/mL 相比:<20ng/mL 发生率比[IRR],2.55[95%CI,1.26-5.15];P=0.009;20 至<30ng/mLIRR,1.69[95%CI,0.75-3.84];P=0.21;30 至<40ng/mLIRR,2.64[95%CI,1.24-5.66];P=0.01)。按维生素 D 水平分层,黑人个体中维生素 D 水平<20ng/mL 的 COVID-19 阳性率估计为 9.72%(95%CI,6.74%-13.41%),维生素 D 水平为 20 至<30ng/mL 的 COVID-19 阳性率估计为 6.47%(95%CI,3.33%-10.28%),维生素 D 水平为 30 至<40ng/mL 的 COVID-19 阳性率估计为 10.10%(95%CI,6.00%-15.47%),维生素 D 水平为 40ng/mL 或更高的 COVID-19 阳性率估计为 3.82%(95%CI,1.78%-6.68%)。在维生素 D 水平为 30ng/mL 或更高的个体中进行的多变量分析发现,COVID-19 检测阳性的 IRR 为 0.97(95%CI,0.94-0.99;P=0.008),每增加 1ng/mL 的维生素 D 总体水平,COVID-19 检测阳性的 IRR 增加 0.95(95%CI,0.91-0.98;P=0.003),黑人个体中维生素 D 水平每增加 1ng/mL。
在这项单中心回顾性队列研究中,与维生素 D 水平为 40ng/mL 或更高的个体相比,黑人个体中维生素 D 水平<40ng/mL 与 COVID-19 风险增加相关,而在维生素 D 水平>30ng/mL 的个体中,维生素 D 水平升高与 COVID-19 风险降低相关。白人个体中未发现显著关联。应进行随机临床试验以研究维生素 D 水平升高至>40ng/mL 是否会影响 COVID-19 风险。